Neurogene Inc.’s Post

Medication adherence to anticoagulants in children represents a crucial piece of the clinical trials puzzle. This guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis, led by Lori Luchtman-Jones and Meghan McGrady, with critical input from Neil Goldenberg MD PhD, Sophie Jones, Aisha Bruce, Mattia Rizzi, Courtney Thornburg, and Kevin Todd outlines critical elements that should be considered when evaluating adherence in this space. #medicationadherence #pediatrics #clinicaltrials

Long-term neurobehavioral & functional outcomes of pediatric #ECMO survivors ➡️ most of patients with impaired function at discharge experience ongoing functional recovery at follow-up but pediatric ECMO survivors have, on average, mild neurobehavioral impairment related to adaptive functioning persisting years after decannulation ➡️ children who receive #ECPR, experience seizures while on #ECLS, have congenital heart disease or pre-ECMO developmental delay, or demonstrate feeding dysfunction at hospital discharge may be at the highest risk of long-term impaired function ASAIO Journal #PedsICU 🔓 https://bit.ly/3TXM9gd

Congenital heart defects (CHDs) are the most common birth defects that affect the structure of a baby’s heart and the way it works, affecting 1% of newborns each year. As a top-ranked center for pediatric heart care, Children's is experienced with treating all kinds of heart problems in infants and children—providing comprehensive cardiac services for congenital and acquired heart disease for babies to young adults, as well as prenatal diagnostics. This #CHDAwarenessWeek, learn more about our top-ranked center for pediatric heart care: https://bit.ly/3jbEHKd.

Managing venous thrombosis in a pediatric patient with short bowel and congenital nephrotic syndromes: a case report emphasizing rivaroxaban level monitoring

In this letter we discussed about the better functions of heart rate variability than hemoglobin as a prognostic factor in pediatric patients with solid organ injury https://lnkd.in/gKuND7AY

Did you know that only 1 in 10 patients achieve seizure freedom with an anti-seizure medication (ASM) after failing more than 2 ASMs? As soon as you identify drug-resistant epilepsy (DRE) in a patient, discuss the next intervention options including VNS Therapy™. The sooner you act, the more likely you are to mitigate the serious consequences of DRE. Every patient with DRE deserves to understand the adjunctive VNS Therapy™ option. The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. To learn more about VNS Therapy™ visit: https://bit.ly/3YCyn2q Important safety information: https://lnkd.in/dSQ3BYgK Reference: Mula M, Zaccara G, Galimberti CA, et al. Epilepsia. 2019;60(6)1114-1123.

Did you know that only 1 in 10 patients achieve seizure freedom with an anti-seizure medication (ASM) after failing more than 2 ASMs? As soon as you identify drug-resistant epilepsy (DRE) in a patient, discuss the next intervention options including VNS Therapy™. The sooner you act, the more likely you are to mitigate the serious consequences of DRE. Every patient with DRE deserves to understand the adjunctive VNS Therapy™ option. The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. To learn more about VNS Therapy™ visit: https://bit.ly/3YCyn2q Important safety information: https://lnkd.in/dSQ3BYgK Reference: Mula M, Zaccara G, Galimberti CA, et al. Epilepsia. 2019;60(6)1114-1123.

Ophthopedia Update:Ocular Manifestations and Outcomes in Children With Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Comparison With Adult Patients: To compare the clinical features and visual outcomes in children and adults with Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). #Ophthalmology #Ophthotwitter #Scicomm

Did you know that only 1 in 10 patients achieve seizure freedom with an anti-seizure medication (ASM) after failing more than 2 ASMs? As soon as you identify drug-resistant epilepsy (DRE) in a patient, discuss the next intervention options including VNS Therapy™. The sooner you act, the more likely you are to mitigate the serious consequences of DRE. Every patient with DRE deserves to understand the adjunctive VNS Therapy™ option. The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. To learn more about VNS Therapy™ visit: https://bit.ly/3YCyn2q Important safety information: https://lnkd.in/dSQ3BYgK Reference: Mula M, Zaccara G, Galimberti CA, et al. Epilepsia. 2019;60(6)1114-1123.

Did you know that only 1 in 10 patients achieve seizure freedom with an anti-seizure medication (ASM) after failing more than 2 ASMs? As soon as you identify drug-resistant epilepsy (DRE) in a patient, discuss the next intervention options including VNS Therapy™. The sooner you act, the more likely you are to mitigate the serious consequences of DRE. Every patient with DRE deserves to understand the adjunctive VNS Therapy™ option. The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. To learn more about VNS Therapy™ visit: https://bit.ly/3YCyn2q Important safety information: https://lnkd.in/dSQ3BYgK Reference: Mula M, Zaccara G, Galimberti CA, et al. Epilepsia. 2019;60(6)1114-1123.